Page 1,928«..1020..1,9271,9281,9291,930..1,9401,950..»

genucel – Intensive New Stem Cell Eye Therapy Treatment …

Posted: November 24, 2014 at 8:45 am

The website you are visiting is owned and operated by Infomercial.TV, Inc. We understand your concerns regarding collection of your personal data. We appreciate your trust and respect your privacy.

Except as otherwise disclosed in this Privacy Policy, we do not sell or disclose information that identifies you personally or makes it possible for other parties to contact them directly without your consent.

Security: We use the Secure Sockets Layer (SSL), an advanced security protocol that protects your credit card information and ensures secure online ordering. SSL Internet connections are encrypted, and thus protect all credit card ordering information, including your name, address and credit card number, so it cannot be read in transit. We use secure technology, privacy protection controls, and restrictions on employee access, to safeguard your personal information.

Collection of Information: We only collect personally identifiable information about you via this website when you provide it in connection with a request for a product, service, or information. For example, if you decide to place an order, we will ask you for your shipping and billing address, phone number, email address, credit card number and its expiration date. When you enter your personally identifiable information on this website, you are giving your consent to the collection, use and disclosure of your personal information as set forth in this Privacy Policy. If you would prefer that we not collect any personally identifiable information from you, please do not provide us with any such information.

We may also collect, store or accumulate certain non-personally identifiable information concerning your use of this website, such as information regarding which of our pages are most popular.

This website is intended for adults. We do not knowingly collect personal information from children under the age of 13. However, if the parent or guardian of a child under 13 believes that the child has provided us with personally identifiable information, the parent or guardian of that child should contact us at info@infomercial.tv if they want this information deleted from our files so that it is not in retrievable form. If we otherwise obtain knowledge that we have personally identifiable information about a child under 13 in retrievable form in our files, we will delete that information from our existing files so that it is not retrievable.

Use of Cookies: We also use cookies to assign identification to your computer. The unique user ID contained within your cookie automatically identifies your computer to our servers every time you visit our website. Cookies by themselves cannot be used to find out the identity of any user, but may be correlated with identity information in our log files. You can turn off the cookie feature by using your browser preference options.

Use of Pixel Tags: We also collect information through the use of pixel tags included in email messages we may send to you. Pixel tags are tiny graphic files, not visible to the human eye, that are included in HTML-encoded email messages. When such a message is opened in an HTML-capable email program, the recipient's computer will access our server to retrieve the pixel tag file, allowing us to record and store, along with the recipient's email address, the date and time the recipient viewed the email message, the fact that the recipient's email program is capable of receiving HTML-encoded email, and other standard logging information. The pixel tag also may see or read cookies.

Third Parties: We may rely on other companies and individuals to perform functions on our behalf. Examples include data analysis firms, customer support specialists, web hosting companies, and fulfillment companies (e.g., companies that fill product orders or coordinate mailings). We may share personally identifiable information with such third parties as appropriate for them to perform their functions. We may also share personally identifiable information with marketing partners or other direct marketers, so they can send you notices about products or services that may be of interest to you. If you do not want to receive marketing communications from them, see the Opt-Out section below.

Our website may offer links to and from other third party sites. These third parties have separate data collection and privacy practices independent from ours, and thus we cannot be responsible for their policies or activities. Please contact those third parties directly if you have questions about their privacy policies.

See the rest here:
genucel - Intensive New Stem Cell Eye Therapy Treatment ...

Posted in Cell Therapy | Comments Off on genucel – Intensive New Stem Cell Eye Therapy Treatment …

Cambridge stem cell pioneer targets China partners

Posted: November 24, 2014 at 8:44 am

Cambridge stem cell pioneer DefiniGEN is in China this week showcasing technology that arguably gives the UK a world lead in countering liver and pancreatic cancer.

The young company is seeking Chinese partners to broaden the reach of the technology which holds a potentially significant payback in regenerative medicine.

With US global stem cell innovator Roger Pedersen among its technology founders, DefiniGEN was founded two years ago to commercialise a stem cell production platform developed at the University of Cambridge.

The platform generates human liver and pancreatic cell types using Nobel Prize winning human Induced Pluripotent Stem Cell (iPSC) technology.

DefiniGEN is visiting Shanghai and Beijing on a trade mission organised by UKTI East of England in partnership with the China-Britain Business Council.

The company is actively looking to partner with Life Science distributors and pharmaceutical drug discovery companies in China. CEO Dr Marcus Yeo and Dr Masashi Matsunaga business development manager for Asia Pacific - are spearheading the initiative.

The visit includes a range of medically-focused ventures from one to one meetings with key players to presentations at UK consulates.

DefiniGEN cells are provided to the drug discovery sector for use in lead optimisation and toxicity programmes.

The companys OptiDIFF platform produces validated libraries of disease-modelled human liver cells for a range of diseases. The phenotype (the composite of an organisms traits) and pathology of the diseases is pre-confirmed in the cells.

The technology provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments.

Continue reading here:
Cambridge stem cell pioneer targets China partners

Posted in Cell Medicine | Comments Off on Cambridge stem cell pioneer targets China partners

New Stem Cell Treatment Found To Cure 'Bubble Baby' Disease

Posted: November 24, 2014 at 8:43 am

Chuck Bednar for redOrbit.com Your Universe Online

A new stem cell gene therapy developed by researchers at UCLA is set to begin clinical trials early next year after the technique reportedly cured 18 children who were born without working immune systems due to a condition known as ADA-deficient Severe Combined Immunodeficiency (SCID) or Bubble Baby disease.

The treatment was developed by Dr. Donald Kohn, a member of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and his colleagues, and according to the university, it is able to identify and correct faulty genes by using the DNA of the youngsters born with this life-threatening condition.

Left untreated, ADA-deficient SCID is often fatal within the first year of a childs life, reports Peter M. Bracke for UCLA. However, after more than three decades of research, Dr. Kohns team managed to develop a gene therapy that can safely restore the immune systems of children with the disease by using their own cells and with no noticeable side effects.

All of the children with SCID that I have treated in these stem cell clinical trials would have died in a year or less without this gene therapy, instead they are all thriving with fully functioning immune systems, Dr. Kohn, who is also a professor of pediatrics and of microbiology, immunology and molecular genetics, said in a recent statement.

Children born with SCID have to be isolated in a controlled environment for their own safety, because without an immune system, they are extremely vulnerable to illnesses and infections that could be deadly. While there are other treatments for ADA-deficient SCID, Dr. Kohn noted that they are not always optimal or feasible for many children. The new technique, however, provides them with a cure, and the chance to live a full healthy life.

SCID is an inherited immunodeficiency that is typically diagnosed about six months after birth, the researchers said, and children with the condition are so vulnerable to infectious diseases that even the common cold could prove fatal to them. This particular form of the condition causes cells to not create ADA, an enzyme essential for the production of the white blood cells which are a vital component of a healthy, normally-functioning immune system.

Approximately 15 percent of all SCID patients are ADA-deficient, according to the university, and these youngsters are typically treated by being injected twice per week with the required enzyme. This is a process that must continue throughout a patients entire life, and even then it doesnt always work to bring their immune systems to optimal levels. Alternately, they could undergo bone marrow transplants from matched siblings, but those matches are rare and the transplanted cells themselves are often rejected by the childs body.

Dr. Kohn and his colleagues tested two therapy regimens on 18 ADA-deficient SCID over the course of two multi-year clinical trials starting in 2009. During the trials, the blood stem cells of the patients were removed from their bone marrow and genetically modified in order to correct the defect. All 18 of the patients were cured.

The technique used a virus delivery system first developed in Dr. Kohns laboratory in the 1990s a technique which inserts the corrected gene that produces the ADA into the blood forming stem cells in the bone marrow. The genetically corrected blood-forming stem cells will they produce the T-cells required to combat infections.

More:
New Stem Cell Treatment Found To Cure 'Bubble Baby' Disease

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on New Stem Cell Treatment Found To Cure 'Bubble Baby' Disease

Sarasota Orthopedic Surgeon Dr. William Bennett Launches New Website

Posted: November 24, 2014 at 5:52 am

Sarasota, FL (PRWEB) November 24, 2014

Dr. William Bennett, one of the top orthopedic surgeons in Florida and owner of Bennett Orthopedics and Sportsmedicine, recently announced the launch of his practices completely redesigned website. The website, which can be found at BennettOrthoSportsMed.com, helps clients connect to the talented doctors PRP, stem cells, arthritis, and pain and injury services.

When treating his patients, Dr. Bennett uses a variety of techniques; he is trained in a variety of procedures, such as nonsurgical and surgical treatment, physical therapy, and stem cell therapy. He is highly regarded in his field, especially because he provides alternatives to surgery when needed. Dr. Bennett has five years of experience and combines it with a minimally invasive approach, ensuring that clients always receive the most attentive, specialized, and comfortable care possible.

According to the website, Dr. Bennetts career has spanned almost 15 years. At present, he is the only doctor serving patients in Tampa to Port Charlotte with custom knee replacements and minimally invasive surgeries. Dr. Bennett is also the only practitioner performing platelet rich plasma (PRP) therapy on clients with orthopedic needs.

With Dr. Bennetts technique, most patients can walk without a cane in two weeks, and some patients can even begin walking within two days.

Some of my former patients remarked that it feels like their normal knee, stated Dr. Bennett. Additionally, I, the surgeon, can not tell the difference between this custom knee and a normal knee when I perform my examinations.

Individuals interested in learning more about Dr. Bennett and PRP therapy in Sarasota can visit the orthopedic surgeons website for additional information. Clients can also subscribe to Dr. Bennetts Facebook, Twitter, YouTube, and LinkedIn accounts for frequent updates about the doctors practice.

About Dr. William Bennett:

Designated one of the Top Orthopedic Surgeons in Sarasota by U.S. News and World Reports, Dr. Bennett has been practicing since 1995. He is a highly skilled, experienced orthopedic surgeon with dual fellowships in Sports medicine-arthroscopy and shoulder surgery. Sarasota Magazine and Castle Connolly Medical ranked him a Top Doctor for Orthopedic Surgery for 2013. For more information, please visit http://www.bennettorthosportsmed.com

See the article here:
Sarasota Orthopedic Surgeon Dr. William Bennett Launches New Website

Posted in Florida Stem Cells | Comments Off on Sarasota Orthopedic Surgeon Dr. William Bennett Launches New Website

Stem Cell Research Article, Embryonic Cells Information …

Posted: November 24, 2014 at 5:51 am

In the beginning, one cell becomes two, and two become four. Being fruitful, they multiply into a ball of many cells, a shimmering sphere of human potential. Scientists have long dreamed of plucking those naive cells from a young human embryo and coaxing them to perform, in sterile isolation, the everyday miracle they perform in wombs: transforming into all the 200 or so kinds of cells that constitute a human body. Liver cells. Brain cells. Skin, bone, and nerve.

The dream is to launch a medical revolution in which ailing organs and tissues might be repairednot with crude mechanical devices like insulin pumps and titanium joints but with living, homegrown replacements. It would be the dawn of a new era of regenerative medicine, one of the holy grails of modern biology.

Revolutions, alas, are almost always messy. So when James Thomson, a soft-spoken scientist at the University of Wisconsin in Madison, reported in November 1998 that he had succeeded in removing cells from spare embryos at fertility clinics and establishing the world's first human embryonic stem cell line, he and other scientists got a lot more than they bargained for. It was the kind of discovery that under most circumstances would have blossomed into a major federal research enterprise. Instead the discovery was quickly engulfed in the turbulent waters of religion and politics. In church pews, congressional hearing rooms, and finally the Oval Office, people wanted to know: Where were the needed embryos going to come from, and how many would have to be destroyed to treat the millions of patients who might be helped? Before long, countries around the world were embroiled in the debate.

Most alarmed have been people who see embryos as fully vested, vulnerable members of society, and who decry the harvesting of cells from embryos as akin to cannibalism. They warn of a brave new world of "embryo farms" and "cloning mills" for the cultivation of human spare parts. And they argue that scientists can achieve the same results using adult stem cells immature cells found in bone marrow and other organs in adult human beings, as well as in umbilical cords normally discarded at birth.

Advocates counter that adult stem cells, useful as they may be for some diseases, have thus far proved incapable of producing the full range of cell types that embryonic stem cells can. They point out that fertility clinic freezers worldwide are bulging with thousands of unwanted embryos slated for disposal. Those embryos are each smaller than the period at the end of this sentence. They have no identifying features or hints of a nervous system. If parents agree to donate them, supporters say, it would be unethical not to do so in the quest to cure people of disease.

Few question the medical promise of embryonic stem cells. Consider the biggest United States killer of all: heart disease. Embryonic stem cells can be trained to grow into heart muscle cells that, even in a laboratory dish, clump together and pulse in spooky unison. And when those heart cells have been injected into mice and pigs with heart disease, they've filled in for injured or dead cells and sped recovery. Similar studies have suggested stem cells' potential for conditions such as diabetes and spinal cord injury.

Critics point to worrisome animal research showing that embryonic stem cells sometimes grow into tumors or morph into unwanted kinds of tissuespossibly forming, for example, dangerous bits of bone in those hearts they are supposedly repairing. But supporters respond that such problems are rare and a lot has recently been learned about how to prevent them.

The arguments go back and forth, but policymakers and governments aren't waiting for answers. Some countries, such as Germany, worried about a slippery slope toward unethical human experimentation, have already prohibited some types of stem cell research. Others, like the U.S., have imposed severe limits on government funding but have left the private sector to do what it wants. Still others, such as the U.K., China, Korea, and Singapore, have set out to become the epicenters of stem cell research, providing money as well as ethical oversight to encourage the field within carefully drawn bounds.

In such varied political climates, scientists around the globe are racing to see which techniques will produce treatments soonest. Their approaches vary, but on one point, all seem to agree: How humanity handles its control over the mysteries of embryo development will say a lot about who we are and what we're becoming.

For more than halfof his seven years, Cedric Seldon has been fighting leukemia. Now having run out of options, he is about to become a biomedical pioneerone of about 600 Americans last year to be treated with an umbilical cord blood transplant.

View post:
Stem Cell Research Article, Embryonic Cells Information ...

Posted in Alaska Stem Cells | Comments Off on Stem Cell Research Article, Embryonic Cells Information …

Stem Cell Cure for "Bubble Baby" Disease (SCID), Pioneered by UCLA’s Don Kohn – Video

Posted: November 23, 2014 at 2:44 pm


Stem Cell Cure for "Bubble Baby" Disease (SCID), Pioneered by UCLA #39;s Don Kohn
On November 18th, 2014, a UCLA research team led by Donald Kohn, M.D., announced a breakthrough gene therapy and stem cell cure for "bubble baby" disease, or severe combined ...

By: California Institute for Regenerative Medicine

More:
Stem Cell Cure for "Bubble Baby" Disease (SCID), Pioneered by UCLA's Don Kohn - Video

Posted in Stem Cell Research | Comments Off on Stem Cell Cure for "Bubble Baby" Disease (SCID), Pioneered by UCLA’s Don Kohn – Video

Stem cell failure 'led to children's deaths' at Great Ormond Street

Posted: November 23, 2014 at 7:49 am

preservation laboratory, where stem cells were kept for use in transplants in children whose bone marrow has been damaged during chemotherapy.

Concerns were first raised when Sophie Ryan-Palmer, 12, who had acute lymphoblastic leukaemia, failed to make progress after her transplant in June 2013, which involved using a donors stem cells rather than her own.

She had been diagnosed with leukaemia at the age of two and had undergone three previous transplants. She began fundraising for cancer charities when she was six.

By October last year the hospital had identified that a higher than usual proportion of eight children who had undergone stem cell transplantation between March and August had suffered what doctors call delayed engraftment. But by the time it stopped freezing stem cells on site at its base in Bloomsbury, central London, and launched an investigation, three of the eight had died.

Ryan Loughran, aged 13 months, from Bournemouth, died on July 10. Sophie, from Sunbury in Middlesex, followed on July 17. Katie Joyce, from Hertfordshire, died on October 6. A fourth patient, Muhanna al-Hayany, aged five, died in August this year. He had come from Kuwait to have the treatment. Following the deaths it was discovered that the method used to freeze the stem cells had inexplicably stopped working and that, although still alive, the cells were unable to mature properly.

At the inquest, Katie Beattie, the barrister representing Katie Joyces family, questioned whether the girls transplant in August should have been suspended, knowing Sophie and Ryan had died the previous month. Great Ormond Street went ahead even though there was plenty of time to stop it, she said.

Doctors from the hospital told St Pancras coroners court that they regretted not halting transplants sooner and Katies life might have been saved if they had. But they said they believed they were doing the right thing by continuing with the transplants because cancer doesnt wait.

Great Ormond Street said it has since overhauled its procedures to prevent further incidents, but is still investigating why the freezing process stopped working.

A spokesman said: Before giving our patients any frozen cells we carried out tests, which are standard across most laboratories in the UK, to ensure they were alive and viable. All of the samples passed these tests, so there was nothing to suggest there was a problem at this stage.

The coroner, Mary Hassell, is expected to deliver verdicts on all four deaths on Tuesday.

See original here:
Stem cell failure 'led to children's deaths' at Great Ormond Street

Posted in Stem Cells | Comments Off on Stem cell failure 'led to children's deaths' at Great Ormond Street

Arachnoiditis Stem Cell Treatment | eHow

Posted: November 23, 2014 at 5:00 am

Ramon Zayas

Ramn Zayas, a retired pharmaceutical and medical professional, attended Penn State University. An accomplished writer, his book and screenplay, Spare Parts were profiled as a doctoral dissertation on psychology and drug addiction. Zayas has been writing for19 years on issues related to healthcare, medical issues, ethics, and political affairs.

As illustrated by the photograph, the brain has three protective layers referred to as meninges. The mid layer, referred to as the arachnoid matter, is a net-like membrane and when this membrane becomes inflamed by injury or other cause, adhesive arachnoiditis (ARC) is the result. Stem cell research is underway in attempts to cure this devastating disease. Most research is done at the National Institutes of Health.

Arachnoiditis Stem Cell Treatment. As illustrated by the photograph, the brain has three protective layers referred to as meninges. The mid layer,...

Arachnoiditis Stem Cell Treatment. As illustrated by the photograph, the brain has three protective layers referred to as meninges. The mid layer,...

Stem Cell Spinal Treatment. Stem cells are the cells from which all other cells in the body ... the non-specialized or "starter"...

Arachnoiditis is a neurological disorder that causes inflammation of a portion of the subarachnoid space, one of the membranes that protect and...

Arachnoiditis Stem Cell Treatment. As illustrated by the photograph, the brain has three protective layers referred to as meninges. The mid layer,...

Arachnoiditis Stem Cell Treatment. ... Stem cell research is on the rise, giving hope to patients and providing treatment for many diseases...

The Centers for Disease Control and Prevention lists heart disease as the No. 1 cause of death in the United States. An...

See the rest here:
Arachnoiditis Stem Cell Treatment | eHow

Posted in Oregon Stem Cells | Comments Off on Arachnoiditis Stem Cell Treatment | eHow

HIV drugs show promise in treating common eye disease

Posted: November 23, 2014 at 4:56 am

Published November 21, 2014

A class of drugs used for three decades by people infected with the virus that causes AIDS may be effective in treating a leading cause of blindness among the elderly.

HIV drugs called nucleoside reverse transcriptase inhibitors (NRTIs), including AZT and three others, blocked age-related macular degeneration in mice and worked well in experiments involving human retinal cells in the laboratory, researchers said on Thursday.

In HIV-infected people, NRTIs block an enzyme the virus uses to create more copies of itself. The new research shows the drugs also block the activity of a biological pathway responsible for activating inflammatory processes in the body.

It is that previously unrecognized quality that makes NRTIs promising for treating macular degeneration as well as graft-versus-host disease, a rarer ailment that can occur after a stem cell or bone marrow transplant, the researchers said.

University of Kentucky ophthalmologist Dr. Jayakrishna Ambati, who led the study published in the journal Science, said macular generation affects an estimated 50 million people worldwide.

"With the aging of the population, it is projected to affect 200 million people by the year 2020. It is therefore critical that we develop new and improved treatments for this disease, which is growing like an epidemic," Ambati said.

Macular degeneration causes cells to die in the macula, a part of the eye located near the center of the retina that permits vision in fine detail.

The chronic disease has two forms: "dry" and "wet." Several treatments exist for "wet" macular degeneration but only about a third of patients get significant vision improvement. There are no approved treatments for the "dry" form, which is much more common but less severe.

The "wet" type occurs when abnormal blood vessels grow under the macula and leak blood and fluid. The "dry" form occurs when cells in the macula break down.

Read more from the original source:
HIV drugs show promise in treating common eye disease

Posted in Kentucky Stem Cells | Comments Off on HIV drugs show promise in treating common eye disease

117.69 /$ (12 a.m.)

Posted: November 23, 2014 at 4:56 am

WASHINGTON A class of drugs used for three decades by people infected with the virus that causes AIDS may be effective in treating a leading cause of blindness among the elderly.

HIV drugs called nucleoside reverse transcriptase inhibitors (NRTIs), including AZT and three others, blocked age-related macular degeneration in mice and worked well in experiments involving human retinal cells in the laboratory, researchers said Thursday.

In HIV-infected people, NRTIs block an enzyme the virus uses to create more copies of itself. The new research shows the drugs also block the activity of a biological pathway responsible for activating inflammatory processes in the body.

It is that previously unrecognized quality that makes NRTIs promising for treating macular degeneration as well as graft-versus-host disease, a rarer ailment that can occur after a stem cell or bone marrow transplant, the researchers said.

University of Kentucky ophthalmologist Dr. Jaya-krishna Ambati, who led the study, published in the journal Science, said macular degeneration affects an estimated 50 million people worldwide.

Macular degeneration causes cells to die in the macula, a part of the eye located near the center of the retina that permits vision in fine detail.

View post:
117.69 /$ (12 a.m.)

Posted in Kentucky Stem Cells | Comments Off on 117.69 /$ (12 a.m.)

Page 1,928«..1020..1,9271,9281,9291,930..1,9401,950..»